The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results
Most recently he served as Chief Operating Officer at Bharat Serums and Vaccines
The Board of Directors of the company recommends a final dividend of Rs. 42 per equity share for the 12 months period ended March 31, 2025
Carson brings with him over two decades of experience in Communications, Public Affairs, and Sustainability
The Pediatric vaccine portfolio delivered double-digit growth and maintained its market leadership in the private market
Strong topline growth driven by solid performance across key brands.
This tie-up will have no impact on any other brands of the company
The company is committed to a new category development in areas like adult Immunization with products like Shingrix to make a positive impact to the lives of the patients in India
Dr. Reddy's Laboratories has been issued a Form 483 with three observations
General Medicine grows 5% and Vaccines 10% led by Shingrix
Subscribe To Our Newsletter & Stay Updated
